• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Recent advances in the ontogeny of drug disposition.药物处置的个体发育中最近的进展。
Br J Clin Pharmacol. 2022 Oct;88(10):4267-4284. doi: 10.1111/bcp.14821. Epub 2021 Apr 15.
2
Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development.在生长发育过程中增加与药物生物转化和药代动力学相关知识基础所面临的挑战与机遇。
Drug Metab Dispos. 2016 Jul;44(7):916-23. doi: 10.1124/dmd.116.071159.
3
Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species.人类和非临床物种肝脏转运体及药物代谢酶的个体发生
Pharmacol Rev. 2021 Apr;73(2):597-678. doi: 10.1124/pharmrev.120.000071.
4
Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology.新生儿的药物处置和临床实践:发育生理学与药理学的对话。
Int J Pharm. 2013 Aug 16;452(1-2):8-13. doi: 10.1016/j.ijpharm.2012.03.035. Epub 2012 Apr 5.
5
Clinical pharmacokinetics in infants and children. A reappraisal.婴幼儿临床药代动力学。重新评估。
Clin Pharmacokinet. 1989;17 Suppl 1:29-67. doi: 10.2165/00003088-198900171-00005.
6
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper.发育药理学的现有知识、挑战与创新:连接儿童专家小组和欧洲发育、围产期和儿科药理学学会白皮书。
Br J Clin Pharmacol. 2022 Dec;88(12):4965-4984. doi: 10.1111/bcp.14958. Epub 2021 Jul 23.
7
Developmental Changes in Pharmacokinetics and Pharmacodynamics.发育过程中的药代动力学和药效学变化。
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S10-S25. doi: 10.1002/jcph.1284.
8
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics.人类膜转运蛋白的发展:药物处置与药物遗传学
Clin Pharmacokinet. 2016 May;55(5):507-24. doi: 10.1007/s40262-015-0328-5.
9
Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics.肝脏药物转运体的个体发生及其与儿科用药的相关性。
Drug Metab Dispos. 2016 Jul;44(7):992-8. doi: 10.1124/dmd.115.067801. Epub 2015 Dec 28.
10
Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.将个体发育纳入生理基于药代动力学模型,以改善儿科药物开发:我们对膜转运体发育变化的了解。
J Clin Pharmacol. 2019 Sep;59 Suppl 1(Suppl 1):S56-S69. doi: 10.1002/jcph.1489.

引用本文的文献

1
Molecular Aspects of Geriatric Pharmacotherapy.老年药物治疗的分子层面
Cells. 2025 Sep 1;14(17):1363. doi: 10.3390/cells14171363.
2
Identifying factors related to sertraline concentrations in child/adolescent and adult patients: insights from a therapeutic drug monitoring service.确定儿童/青少年及成年患者中与舍曲林浓度相关的因素:来自治疗药物监测服务的见解
BMC Psychiatry. 2025 Jun 6;25(1):590. doi: 10.1186/s12888-025-07033-6.
3
Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study.淋巴瘤患儿、青少年及青年中CYP3A4、CYP2C19和CYP2D6的表型转换:PEGASUS研究的原理与设计
Clin Transl Sci. 2025 Apr;18(4):e70209. doi: 10.1111/cts.70209.
4
Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome.用于新生儿阿片类药物戒断综合征的昂丹司琼的贝叶斯群体药代动力学建模
Clin Transl Sci. 2025 Feb;18(2):e70147. doi: 10.1111/cts.70147.
5
Advancing Precision Medicine in Paediatrics: Past, present and future.推进儿科精准医学:过去、现在与未来。
Camb Prism Precis Med. 2023 Jan 10;1:e11. doi: 10.1017/pcm.2022.14. eCollection 2023.
6
Editorial: Genetics and ontogeny in precision therapeutics for children.社论:儿童精准治疗中的遗传学与个体发生学
Front Genet. 2023 Oct 27;14:1308169. doi: 10.3389/fgene.2023.1308169. eCollection 2023.
7
Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations.创新、机遇与挑战:预测特殊人群中药物代谢酶和转运体活性改变
Drug Metab Dispos. 2023 Dec;51(12):1547-1550. doi: 10.1124/dmd.123.001453. Epub 2023 Sep 29.
8
Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.他克莫司药代动力学受 CYP3A5、年龄和氟康唑伴随用药的影响,在儿科肾移植患者中。
Clin Transl Sci. 2023 Oct;16(10):1768-1778. doi: 10.1111/cts.13571. Epub 2023 Jun 26.
9
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence.青少年时期细胞色素 P450 2D6(CYP2D6)活性的纵向研究。
Clin Transl Sci. 2022 Oct;15(10):2514-2527. doi: 10.1111/cts.13380. Epub 2022 Aug 23.
10
Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review.炎症对儿科细胞色素 P450 活性的影响:系统评价。
Clin Pharmacokinet. 2021 Dec;60(12):1537-1555. doi: 10.1007/s40262-021-01064-4. Epub 2021 Aug 31.

本文引用的文献

1
Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.肝 CYP3A4 个体发育功能对儿科生理药代动力学/药效学模型中药物-药物相互作用风险的影响:关键文献回顾和伊伐布雷定案例研究。
Clin Pharmacol Ther. 2021 Jun;109(6):1618-1630. doi: 10.1002/cpt.2134. Epub 2020 Dec 31.
2
Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.基于生理药代动力学模型的模拟应用于监管决策及其对美国处方信息的影响:美国 FDA 临床药理学办公室 2018-2019 年提交文件的更新。
J Clin Pharmacol. 2020 Oct;60 Suppl 1:S160-S178. doi: 10.1002/jcph.1767.
3
Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters.液体活检可实现肝脏酶和转运蛋白丰度及个体间变异性的定量分析。
Clin Pharmacol Ther. 2021 Jan;109(1):222-232. doi: 10.1002/cpt.2102. Epub 2020 Nov 25.
4
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy.模型指导下的精准剂量调整:个体化药物治疗的背景、要求、验证、实施和未来方向。
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:225-245. doi: 10.1146/annurev-pharmtox-033020-113257. Epub 2020 Oct 9.
5
Use of a physiologically based pharmacokinetic-pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial.使用基于生理学的药代动力学-药效学模型进行儿科临床试验的初始剂量预测和递增。
Br J Clin Pharmacol. 2021 Mar;87(3):1378-1389. doi: 10.1111/bcp.14528. Epub 2020 Sep 6.
6
The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study.药物特性和转运体的个体发育对肾小球滤过和主动分泌途径的儿科肾清除率的影响:基于模拟的研究。
AAPS J. 2020 Jun 21;22(4):87. doi: 10.1208/s12248-020-00468-7.
7
Personalized Mapping of Drug Metabolism by the Human Gut Microbiome.人肠道微生物组对药物代谢的个性化映射。
Cell. 2020 Jun 25;181(7):1661-1679.e22. doi: 10.1016/j.cell.2020.05.001. Epub 2020 Jun 10.
8
A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.一个基于生理学的药代动力学框架,以支持新生儿治疗性低温期间的药物开发和剂量精准度。
Front Pharmacol. 2020 May 13;11:587. doi: 10.3389/fphar.2020.00587. eCollection 2020.
9
Developmental patterns in human blood-brain barrier and blood-cerebrospinal fluid barrier ABC drug transporter expression.人类血脑屏障和血脑脊液屏障 ABC 药物转运体表达的发育模式。
Histochem Cell Biol. 2020 Sep;154(3):265-273. doi: 10.1007/s00418-020-01884-8. Epub 2020 May 24.
10
Physiologically-based pharmacokinetic models for children: Starting to reach maturation?基于生理学的儿童药代动力学模型:开始接近成熟?
Pharmacol Ther. 2020 Jul;211:107541. doi: 10.1016/j.pharmthera.2020.107541. Epub 2020 Apr 1.

药物处置的个体发育中最近的进展。

Recent advances in the ontogeny of drug disposition.

机构信息

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.

Schools of Medicine and Pharmacy, University of Missouri-Kansas City, MO, USA.

出版信息

Br J Clin Pharmacol. 2022 Oct;88(10):4267-4284. doi: 10.1111/bcp.14821. Epub 2021 Apr 15.

DOI:10.1111/bcp.14821
PMID:33733546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8986831/
Abstract

Developmental changes that occur throughout childhood have long been known to impact drug disposition. However, pharmacokinetic studies in the paediatric population have historically been limited due to ethical concerns arising from incorporating children into clinical trials. As such, much of the early work in the field of developmental pharmacology was reliant on difficult-to-interpret in vitro and in vivo animal studies. Over the last 2 decades, our understanding of the mechanistic processes underlying age-related changes in drug disposition has advanced considerably. Progress has largely been driven by technological advances in mass spectrometry-based methods for quantifying proteins implicated in drug disposition, and in silico tools that leverage these data to predict age-related changes in pharmacokinetics. This review summarizes our current understanding of the impact of childhood development on drug disposition, particularly focusing on research of the past 20 years, but also highlighting select examples of earlier foundational research. Equally important to the studies reviewed herein are the areas that we cannot currently describe due to the lack of research evidence; these gaps provide a map of drug disposition pathways for which developmental trends still need to be characterized.

摘要

儿童期发生的发育变化长期以来一直被认为会影响药物处置。然而,由于将儿童纳入临床试验引起的伦理问题,儿科人群的药代动力学研究在历史上一直受到限制。因此,该领域的许多早期工作依赖于难以解释的体外和体内动物研究。在过去的 20 年中,我们对药物处置中与年龄相关变化相关的机制过程的理解有了很大的提高。这主要得益于基于质谱的定量方法在定量药物处置中涉及的蛋白质方面的技术进步,以及利用这些数据预测药代动力学中与年龄相关变化的计算工具。本文综述了我们目前对儿童发育对药物处置的影响的理解,特别是重点介绍了过去 20 年的研究,但也强调了早期基础研究的一些选择示例。与本文综述的研究同样重要的是,由于缺乏研究证据,我们目前无法描述的领域;这些差距为发育趋势仍需要特征化的药物处置途径提供了一张地图。